A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP

Inclusion Criteria:

• Male and female participants aged between 18 - 85 years (inclusive) at the start ofscreening will be included.

• Subjects must have a body mass index (BMI) within the range of 18 - 45 kg/m2. BMI =Body weight (kg) / [Height (m)]2

• Documented spontaneous myocardial infarction (MI) (diagnosed according to theuniversal MI criteria with or without evidence of ST segment elevation) at least 30days before the start of screening.

• Participants must have hsCRP levels ≥ 2 mg/L at two timepoints during screening.Screening values must be separated by a minimum of 8 days. The initial hsCRP valuemust be a minimum of 30 days after the qualifying MI or after any percutaneouscoronary intervention (PCI) performed separately from the qualifying MI.

• For participants on statin therapy (HMG-CoA reductase inhibitor), as clinicallyindicated, participants must be on a stable regimen (at least 4 weeks beforerandomization), with no planned statin dose changes over the course of the trialtreatment period. Unplanned statin dose changes during the trial treatment periodmay occur.

Exclusion Criteria:

• Patients receiving concomitant medications that are known to be strong or moderateinducers of cytochrome CYP2C9 enzyme and/or strong inducers of CYP3A, stronginhibitors of CYP2C9 and/or strong or moderate inhibitors of CYP3A and the treatmentcannot be discontinued or switched to a different medication within 5 half-lives or 1 week (whichever is longer) prior to Day 1 and for the duration of the study.

• Patients with suspected or proven immunocompromised state at screening

• History of ongoing, chronic, or major recurrent infectious disease, at thediscretion of the investigator, at the start of screening.

• Use of any biologic drugs targeting the immune system within 26 weeks of Day 1

• Multi-vessel Coronary Artery Bypass Graft (CABG) surgery within the past 6 monthsprior to the start of screening.

• Symptomatic Class IV heart failure (New York Heart Association) at the start ofscreening.

• Planned coronary revascularization (PCI or CABG) or any other major surgicalprocedure during the study.